# Kim Seth

> Kim Seth, Ph.D., is the founding President & CEO of Nilo Therapeutics, a New York biotech that launched in October 2025 with a $101 million Series A to build medicines that talk to the immune system through the brain. A Harvard-trained neurobiologist turned dealmaker, he spent 25-plus years moving between Goldman Sachs, Pfizer, and Repare Therapeutics - where he helped take a precision-oncology startup from pre-Series A to IPO - before betting his own career on the strange idea that the vagus nerve might be the most underused drug target in autoimmune disease.

- **Role:** President & CEO at Nilo Therapeutics
- **Organizations:** Nilo Therapeutics, Repare Therapeutics, Pfizer, Goldman Sachs
- **Nationality:** United States
- **Education:** B.A. in Economics, cum laude, Harvard College, Ph.D. in Neurobiology, Harvard University (Division of Medical Sciences), Ecole Polytechnique
- **Known for:** Founding President & CEO of Nilo Therapeutics, launched October 2025 with a $101 million Series A, As CBO of Repare Therapeutics, helped scale the company from pre-Series A through Series B and IPO, Led business development generating over $250 million in financing through partnerships representing more than $4 billion in total potential value

## Career timeline

- **Early career** — Large-cap and specialty pharmaceuticals research analyst at Goldman Sachs
- **—** — Leadership roles in business development, strategy and operations at biopharma companies including Pfizer
- **—** — Chief Business Officer / EVP, Head of Business and Corporate Development at Repare Therapeutics - scaled the company from pre-Series A through Series B and IPO
- **2025** — Appointed founding President, CEO and board director of Nilo Therapeutics at its $101M Series A launch

## Achievements

- Founding President & CEO of Nilo Therapeutics, launched October 2025 with a $101 million Series A
- As CBO of Repare Therapeutics, helped scale the company from pre-Series A through Series B and IPO
- Led business development generating over $250 million in financing through partnerships representing more than $4 billion in total potential value
- Established Repare's US business operations and struck partnerships with companies including Roche and Bristol Myers Squibb
- Earned a Ph.D. in Neurobiology from Harvard alongside a cum laude economics degree

## Latest updates

- **2025-10** — Nilo Therapeutics launched out of stealth with a $101 million Series A and named Kim Seth founding President & CEO.

## Links

- Website: https://nilotx.com
- LinkedIn: http://www.linkedin.com/in/kim-seth-ph-d-12b387

---

Profile page: https://yespress.io/kim-seth
Published by YesPress — https://yespress.io
Last updated: 2026-06-11